Xeris Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01, revenue of $29.6M beats by $0.48M

Nov. 09, 2022 7:11 AM ETXeris Biopharma Holdings, Inc. (XERS)By: Pranav Ghumatkar, SA News Editor
  • Xeris Pharmaceuticals press release (NASDAQ:XERS): Q3 GAAP EPS of -$0.16 beats by $0.01.
  • Revenue of $29.6M (+168.4% Y/Y) beats by $0.48M.
  • Ended Q3 with $93.4M in cash, cash equivalents and short-term investments; raises 2022 year-end cash balance guidance from $90M-$110M to $110M-$120M
  • Remains on track to achieve $50M in synergies by year-end 2022 and cash flow breakeven by year-end 2023
  • Reported positive topline results from its Phase 1 study of subcutaneous levothyroxine (XP-8121)
  • Published the longer-term effects of levoketoconazole (Recorlev®) from extended evaluation of SONICS study in ‘European Journal of Endocrinology.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.